Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Perhexiline.

Houman Ashrafian1, John D Horowitz, Michael P Frenneaux

  • 1Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK. houman.ashrafian@cardiov.ox.ac.uk

Cardiovascular Drug Reviews
|April 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CMR Reveals the Influence of Trigger and Classification on the Myocardial Tissue Response in Takotsubo Syndrome.

Circulation. Cardiovascular imaging·2026
Same author

Mechanical circulatory support for cardiogenic shock in takotsubo syndrome.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes.

Circulation·2025
Same author

Regulatory T cells attenuate chronic inflammation and cardiac fibrosis in hypertrophic cardiomyopathy.

Science translational medicine·2025
Same author

Explosive discovery, surprising future: The extraordinary journey of nitroglycerin, nitroderivatives and nitric oxide.

Vascular pharmacology·2025
Same author

Magnetic Resonance Imaging for Improved Brain Tumor Detection.

bioRxiv : the preprint server for biology·2025
Same journal

Therapeutic effects of guggul and its constituent guggulsterone: cardiovascular benefits.

Cardiovascular drug reviews·2007
Same journal

Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.

Cardiovascular drug reviews·2007
Same journal

A multiple ion channel blocker, NIP-142, for the treatment of atrial fibrillation.

Cardiovascular drug reviews·2007
Same journal

Serofendic acid, a substance extracted from fetal calf serum, as a novel drug for cardioprotection.

Cardiovascular drug reviews·2007
Same journal

Clinical use of sirolimus-eluting stents.

Cardiovascular drug reviews·2007
Same journal

A review of clinical trials with eptifibatide in cardiology.

Cardiovascular drug reviews·2007
See all related articles

Perhexiline effectively treats angina by improving heart efficiency. Genetic testing and plasma monitoring enable safe use by managing side effects in patients with specific metabolic profiles.

Area of Science:

  • Pharmacology
  • Cardiology
  • Drug Metabolism

Background:

  • Perhexiline, an anti-anginal drug, saw reduced use due to neurotoxicity and hepatotoxicity.
  • The mechanisms behind perhexiline's efficacy and toxicity were previously unclear.

Purpose of the Study:

  • To elucidate perhexiline's pharmacology, mechanism of action, and toxicity.
  • To discuss the role of therapeutic plasma monitoring and pharmacogenetics in its safe reintroduction and expanded use.

Main Methods:

  • Review of perhexiline's pharmacological properties, including its inhibition of carnitine palmitoyltransferase.
  • Analysis of the link between CYP2D6 gene mutations, impaired metabolism, and perhexiline-induced toxicity.
  • Examination of clinical data supporting the safety and efficacy of perhexiline with dose adjustments.

Related Experiment Videos

Main Results:

  • Perhexiline inhibits carnitine palmitoyltransferase, shifting metabolism to carbohydrates for increased myocardial efficiency and anti-anginal effects.
  • Toxicity is linked to high plasma concentrations in individuals with impaired CYP2D6 metabolism.
  • Therapeutic plasma monitoring and dose modification in susceptible patients mitigate side effects.

Conclusions:

  • Perhexiline's mechanism of action and toxicity are now understood, allowing for safer clinical application.
  • Therapeutic plasma monitoring and pharmacogenetics facilitate the safe reintroduction and potential expansion of perhexiline use.
  • Perhexiline demonstrates significant efficacy in refractory angina and chronic heart failure, with potential for other cardiac conditions.